share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/09/13 20:56

Moomoo AI 已提取核心訊息

Allarity Therapeutics announced the appointment of Alexander Epshinsky as its new Chief Financial Officer, effective September 12, 2024, following Joan Y. Brown's resignation. Epshinsky, a CPA with extensive experience in pharmaceutical and biotech companies, will receive a $340,000 annual base salary, RSUs worth $160,000, and a $50,000 signing bonus.The company has amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, increasing the placement shares amount to $50 million. This modification comes as the company plans to resume its financing initiatives after a two-month pause to support its strategic goals and growth plans.Under Epshinsky's employment agreement, he is eligible for an annual bonus of up to 30% of base salary starting 2025, with prorated bonus for 2024. The agreement includes severance provisions of six months' salary for termination without cause or following a change of control.
Allarity Therapeutics announced the appointment of Alexander Epshinsky as its new Chief Financial Officer, effective September 12, 2024, following Joan Y. Brown's resignation. Epshinsky, a CPA with extensive experience in pharmaceutical and biotech companies, will receive a $340,000 annual base salary, RSUs worth $160,000, and a $50,000 signing bonus.The company has amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, increasing the placement shares amount to $50 million. This modification comes as the company plans to resume its financing initiatives after a two-month pause to support its strategic goals and growth plans.Under Epshinsky's employment agreement, he is eligible for an annual bonus of up to 30% of base salary starting 2025, with prorated bonus for 2024. The agreement includes severance provisions of six months' salary for termination without cause or following a change of control.
Allarity Therapeutics宣佈任命亞歷山大·埃普辛斯基爲其新任財務長,任職日期爲2024年9月12日,此前喬安·Y·布朗辭職。埃普辛斯基是擁有豐富藥品和生物科技公司經驗的註冊會計師,將獲得34萬美元的年基本工資、價值16萬美元的限制性股票單位和5萬美元的簽約獎金。該公司已修改與Ascendiant Capital 資本市場的市場發行銷售協議,將股份發放數量增加至5000萬美元。這一修改發生在該公司計劃在暫停兩個月後恢復融資舉措,以支持其戰略目標和增長計劃。根據埃普辛斯基的僱傭協議,他有資格在2025年開始獲得最多30%的年獎金,並將爲2024年按比例計算獎金。協議包括因無故解僱或控制權變更而終止時的六個月薪酬的遣散費條款。
Allarity Therapeutics宣佈任命亞歷山大·埃普辛斯基爲其新任財務長,任職日期爲2024年9月12日,此前喬安·Y·布朗辭職。埃普辛斯基是擁有豐富藥品和生物科技公司經驗的註冊會計師,將獲得34萬美元的年基本工資、價值16萬美元的限制性股票單位和5萬美元的簽約獎金。該公司已修改與Ascendiant Capital 資本市場的市場發行銷售協議,將股份發放數量增加至5000萬美元。這一修改發生在該公司計劃在暫停兩個月後恢復融資舉措,以支持其戰略目標和增長計劃。根據埃普辛斯基的僱傭協議,他有資格在2025年開始獲得最多30%的年獎金,並將爲2024年按比例計算獎金。協議包括因無故解僱或控制權變更而終止時的六個月薪酬的遣散費條款。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息